Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Olema Pharmaceuticals, Inc.

OLMA · Nasdaq · CIK 0001750284 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

2 Form 4 transaction lines observed in the same window
2 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2025-01-08 · Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P. · $1.7M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Harmon CyrusDirector
▼▼
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-01-08 · Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P..

Recent Form 4 activity

0Purchases
25Sales
19Other Form 4 lines
15SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
14,696,219
Previous report
16,068,469
Avg daily volume
1,441,960
Days to cover
10.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-01-08Bain Capital Life Sciences Fund IV, L.P.; Bain Capital Life Sciences IV General Partner, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Opportunities IV GP, LLC; Bain Capital Life Sciences Opportunities IV, L.P.Purchase (P)Common Stock300,000USD 5.76USD 1,728,000SEC filing ↗
2024-12-17Graham G. WalmsleyPurchase (P)Common Stock700,761USD 6.75USD 4,730,137SEC filing ↗
2024-12-13Graham G. WalmsleyPurchase (P)Common Stock700,761USD 6.75USD 4,730,137SEC filing ↗
2023-12-06Asefaw Senai; Paradigm BioCapital Advisors GP LLC; Paradigm BioCapital International Fund Ltd.; Paradigm Biocapital Advisors LPPurchase (P)Common Stock, par value $0.0001 per share100,000USD 11.60USD 1,160,000SEC filing ↗
2023-12-05Graham G. WalmsleyPurchase (P)Common Stock131,870USD 14.19USD 1,871,445SEC filing ↗
2023-09-12Graham G. WalmsleyPurchase (P)Common Stock508,130USD 9.84USD 4,999,999SEC filing ↗
2023-09-12BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common stock, $0.0001 par value1,505,932USD 9.84USD 14,818,371SEC filing ↗
2023-04-06Kovacs Shane William CharlesPurchase (P)Common Stock10,000USD —USD —SEC filing ↗
2022-09-21Bohen SeanPurchase (P)Common Stock20,000USD —USD —SEC filing ↗
2022-09-02Kovacs Shane William CharlesPurchase (P)Common Stock20,000USD —USD —SEC filing ↗
2022-06-10BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common stock, $0.0001 par value200,000USD 4.03USD 806,000SEC filing ↗
2021-11-30BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common stock, $0.0001 par value739,675USD 9.39USD 6,945,548SEC filing ↗
2020-11-23Graham G. WalmsleyPurchase (P)Common Stock1,160,000USD 19.00USD 22,040,000SEC filing ↗
2020-11-23Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LPPurchase (P)Common Stock425,000USD 19.00USD 8,075,000SEC filing ↗
2020-11-19BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK NPurchase (P)Common stock, $0.0001 par value1,135,334USD 19.00USD 21,571,346SEC filing ↗

Form 4 evidence

44 transaction lines in the latest 365-day window; 253 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-24Harmon CyrusSale (S)Common Stock12,500USD 11.71USD 146,375SEC filing ↗
2026-07-23Harmon CyrusSale (S)Common Stock12,500USD 11.58USD 144,750SEC filing ↗
2026-03-04Mitchell ShawnteSale (S)Comon Stock233USD 24.69USD 5,753SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-24Harmon CyrusSale (S)Common Stock12,500USD 11.71USD 146,375SEC filing ↗
2026-07-23Harmon CyrusSale (S)Common Stock12,500USD 11.58USD 144,750SEC filing ↗
2026-03-04Mitchell ShawnteSale (S)Comon Stock233USD 24.69USD 5,753SEC filing ↗
2026-03-04Mitchell ShawnteSale (S)Common Stock24,767USD 24.25USD 600,600SEC filing ↗
2026-03-04Mitchell ShawnteOption exercise / conversion (M)Common Stock25,000USD 4.37USD 109,250SEC filing ↗
2026-03-03Mitchell ShawnteSale (S)Common Stock15,000USD 23.01USD 345,150SEC filing ↗
2026-03-03Mitchell ShawnteOption exercise / conversion (M)Common Stock15,000USD 4.37USD 65,550SEC filing ↗
2026-02-02Austin Sasha LuAward / grant (A)Common Stock11,700USD 0.00USD 0SEC filing ↗
2026-01-20Harmon CyrusSale (S)Common Stock10,000USD 26.88USD 268,800SEC filing ↗
2026-01-15Kovacs Shane William CharlesSale (S)Common Stock100,000USD 28.73USD 2,873,000SEC filing ↗
2026-01-14Harmon CyrusSale (S)Common Stock3,489USD 29.12USD 101,600SEC filing ↗
2026-01-14Myles David C.Sale (S)Common Stock50,000USD 28.87USD 1,443,651SEC filing ↗
2026-01-14Myles David C.Option exercise / conversion (M)Common Stock50,000USD 4.87USD 243,500SEC filing ↗
2026-01-13Kovacs Shane William CharlesSale (S)Common Stock3,822USD 28.01USD 107,054SEC filing ↗
2026-01-13Myles David C.Sale (S)Common Stock50,000USD 27.60USD 1,380,178SEC filing ↗
2026-01-13Myles David C.Option exercise / conversion (M)Common Stock50,000USD 4.87USD 243,500SEC filing ↗
2026-01-12Myles David C.Sale (S)Common Stock10,000USD 28.34USD 283,400SEC filing ↗
2025-12-26Bohen SeanGift (G)Common Stock8,500USD 0.00USD 0SEC filing ↗
2025-12-23Zojwalla NaseemSale (S)Common Stock99,509USD 27.66USD 2,752,419SEC filing ↗
2025-12-23Zojwalla NaseemOption exercise / conversion (M)Common Stock50,000USD 7.02USD 351,000SEC filing ↗
2025-12-22Harmon CyrusSale (S)Common Stock2,881USD 28.53USD 82,195SEC filing ↗
2025-12-22Zojwalla NaseemSale (S)Common Stock100,000USD 28.04USD 2,804,000SEC filing ↗
2025-12-22Zojwalla NaseemOption exercise / conversion (M)Common Stock50,000USD 14.07USD 703,392SEC filing ↗
2025-12-19Zojwalla NaseemSale (S)Common Stock70,000USD 28.20USD 1,973,729SEC filing ↗
2025-12-19Zojwalla NaseemOption exercise / conversion (M)Common Stock40,000USD 15.25USD 610,000SEC filing ↗
2025-12-19Myles David C.Sale (S)Common Stock51,000USD 30.46USD 1,553,544SEC filing ↗
2025-12-19Myles David C.Gift (G)Common Stock9,000USD 0.00USD 0SEC filing ↗
2025-12-19CLARK IAN TSale (S)Common Stock264,800USD 29.73USD 7,873,109SEC filing ↗
2025-12-19CLARK IAN TOption exercise / conversion (M)Common Stock264,800USD 4.61USD 1,220,382SEC filing ↗
2025-12-08Kovacs Shane William CharlesGift (G)Common Stock75,000USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerOLMA
CIK0001750284
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history253 transaction lines from 2020-06-15 to 2026-07-24
24 P purchase lines · 131 S sale lines · 98 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.